Filed with ASX · · 3 pages · English
Invion Ltd. has announced the conclusion of patient recruitment for its Phase I Non-Melanoma Skin Cancer trial, with preliminary data indicating a strong safety profile and promising efficacy signals, supporting advancement to Phase II trials. The Safety Review Committee found no serious adverse events and a high disease control rate among patients treated, reinforcing the potential of Invion's treatment. Next steps include planning a Phase II trial that may target advanced skin cancers with significant unmet clinical needs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX ANNOUNCEMENT Invion Limited ABN 76 094 730 417 Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 P: +61 3 9692 7222 W: www.inviongroup.com INVION CONCLUDES RECRUITMENT IN NON-MELANOMA SKIN CANCER PHASE 1 TRIAL WITH PRELIM DATA SUPPORTING ADVANCEMENT TO PHASE 2 Highlights: •...
Follow Invion into a list and get an email when it puts out news.
Follow Invion